Imunon, Inc.
CLSN
Rankning i aktier
#34853
Imunon, Inc. is a biotechnology firm in the clinical development stage,... Imunon, Inc. is a biotechnology firm in the clinical development stage, dedicated to innovating and commercializing DNA-centric immunotherapies, vaccines, and targeted chemotherapy solutions. Its primary pipeline assets include GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a unique formulation of doxorubicin encapsulated in heat-activated liposomes, currently being assessed for a variety of cancer indications. Furthermore, the company is advancing two early-phase platform technologies aimed at developing nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA treatments. Established in 1982, Imunon, Inc. maintains its operational base in Lawrenceville, New Jersey.
Aktiekurs
$1.96
Senast synkroniserad: 2022-09-20
Marknadsvärde
$4.46M
Förändring (1 dag)
0.00%
Förändring (1 år)
122.70%
Land
US
Handel Imunon, Inc. (CLSN)
Kategori
Healthcare
Aktiekurshistorik för Imunon, Inc. (CLSN)
Högsta slutkurs: $0.93 den 2025-01-01
Lägsta slutkurs: $37.95 den 2018-01-01
Lägsta slutkurs: $37.95 den 2018-01-01
Aktiekurshistorik för Imunon, Inc. från 2018 till 2026
Årlig aktiekursutveckling
| År | Prestanda |
|---|---|
| 2025 | 10.76% |
| 2024 | -3.79% |
| 2023 | -36.24% |
| 2022 | -86.26% |
| 2021 | -10.52% |
| 2020 | -70.48% |
| 2018 | 0.00% |
Aktiekurs för liknande företag eller konkurrenter
| Företag | Aktiekurs | Förändring 1år% | Land |
|---|---|---|---|
| $536.13 | 25.72% |
US
|
|
| $200.12 | 645.31% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $880.01 | 8.09% |
NL
|
